中国组织工程研究

中国组织工程研究 ›› 2012, Vol. 16 ›› Issue (32): 6071-6075.doi: 10.3969/j.issn.2095-4344.2012.32.034

• 干细胞临床实践 clinical practice of stem cells • 上一篇    下一篇

自体骨髓间充质干细胞回输治疗脑卒中30例

陈文明1，邹清雁2，卢建军1，胡运新1，胡琼力1，李志刚1，曾昭龙1   

  1. 1广东三九脑科医院神经内科，广东省广州市 510510；
    2广州和竺生物科技有限公司，广东省广州市 510663
  • 收稿日期:2012-01-14 修回日期:2012-04-18 出版日期:2012-08-05 发布日期:2012-08-05
  • 作者简介:陈文明★，男，1963年生，副主任医师，浙江省义乌市人，1995年南方医科大学毕业，硕士，主要从事自体骨髓干细胞的基础研究及某些难治性神经系统疾病的临床应用工作。 wenming6311@tom.com

Reinfusion of autologous bone marrow mesenchymal stem cells for treatment of stroke in 30 cases

Chen Wen-ming1, Zou Qing-yan2, Lu Jian-jun1, Hu Yun-xin1, Hu Qiong-li1, Li Zhi-gang1, Zen Zhao-long1   

  1. 1Department of Neurology, Guangdong 999 Brain Hospital, Guangzhou 510510, Guangdong Province, China;
    2Guangzhou Hezu Biotech Co.,Ltd., Guangzhou 510663, Guangdong Province, China
  • Received:2012-01-14 Revised:2012-04-18 Online:2012-08-05 Published:2012-08-05
  • About author:Chen Wen-ming★, Master, Associate chief physician, Department of Neurology, Guangdong 999 Brain Hospital, Guangzhou 510540, Guangdong Province, China wenming6311@tom.com

PDF

396

被引次数

1

摘要：

背景：自体骨髓间充质干细胞对神经功能缺损的修复有一定的作用，但对脑卒中的治疗作用尚缺乏较为严格的对照研究。
目的：观察自体骨髓间充质干细胞回输治疗脑卒中患者的临床效果。
方法：对30例要求进行自体骨髓间充质干细胞回输治疗的脑卒中住院患者予以自体骨髓间充质干细胞回输治疗，同时期30例未接受干细胞治疗的脑卒中住院患者作为对照组。用《临床神经功能缺损程度评分量表》评分作为疗效评估指标，观察治疗后6个月两组的神经功能恢复情况及其差异，并观察其安全性。
结果及结论：治疗后6个月时两组《临床神经功能缺损程度评分量表》分值均下降，自身对照差异有显著性意义(P < 0.05)；干细胞治疗组分值下降更多，与对照组下降分值比较，差异有显著性意义(P < 0.05)。提示自体骨髓间充质干细胞移植治疗脑血管病有确切效果并且安全。但有待于扩大样本量，并且严格随机、双盲、对照的临床观察进一步证实。

关键词: 自体骨髓间充质干细胞, 脑卒中, 移植, 神经功能缺损评分, 脑血管病

Abstract:

BACKGROUND: Autologous bone marrow mesenchymal stem cells have certain effects on repairing the neurologic impairment, but there are no well-controlled studies describing autologous bone marrow mesenchymal stem cells for treatment of stroke.
OBJECTIVE: To observe the clinical effects of autologous bone marrow mesenchymal stem cell reinfusion for treatment of stroke.
METHODS: Thirty stroke patients treated by autologous bone marrow mesenchymal stem cells reinfusion were included in the experimental group. Thirty stroke patients who did not receive autologous bone marrow mesenchymal stem cell reinfusion were included in the control group. The National Institutes of Health Stroke Scale (NIHSS) was used to assess the clinical efficacy. At 6 months after treatment, the neurological function recovery and the safety of autologous bone marrow mesenchymal stem cells were investigated.
RESULTS AND CONCLUSION: The NIHSS score decreased significantly in the two groups after 6 months of treatment (P < 0.05). There was significant difference in NIHSS score between before and after treatment (P < 0.05). The NIHSS score of the control group decreased significantly than that of the experimental group (P < 0.05). Autologous bone marrow mesenchymal stem cell reinfusion for treatment of cerebrovascular disease is effective and safe. But this needs to be further confirmed by strictly randomized, double-blinded, controlled clinical studies involving a larger number of samples.

中图分类号: